These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25165545)

  • 1. New agents for the treatment of hepatitis C in patients co-infected with HIV.
    Munteanu DI; Rockstroh JK
    Ther Adv Infect Dis; 2013 Apr; 1(2):71-80. PubMed ID: 25165545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
    Younossi ZM; Singer ME; Mir HM; Henry L; Hunt S
    J Hepatol; 2014 Mar; 60(3):530-7. PubMed ID: 24269472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing treatment in HIV/HCV coinfection.
    Puoti M; Rossotti R; Travi G; Panzeri C; Morreale M; Chiari E; Cocca G; Orso M; Moioli MC
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S355-62. PubMed ID: 24091116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
    Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
    J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
    Coilly A; Roche B; Dumortier J; Leroy V; Botta-Fridlund D; Radenne S; Pageaux GP; Si-Ahmed SN; Guillaud O; Antonini TM; Haïm-Boukobza S; Roque-Afonso AM; Samuel D; Duclos-Vallée JC
    J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.
    Eron JJ; Lalezari J; Slim J; Gathe J; Ruane PJ; Wang C; Elion R; Blick G; Khatri A; Hu YB; Gibbons K; Fredrick L; Co M; D'Amico R; Da Silva-Tillmann B; Trinh R; Sulkowski MS
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19500. PubMed ID: 25394009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
    Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
    Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
    Miailhes P; Gilbert C; Lacombe K; Arends JE; Puoti M; Rockstroh JK; Sogni P; Fontaine H; Rosenthal E; Winnock M; Loko MA; Wittkop L; Dabis F; Salmon D;
    Liver Int; 2015 Sep; 35(9):2090-9. PubMed ID: 25650873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure.
    Mandorfer M; Steiner S; Schwabl P; Payer BA; Aichelburg MC; Grabmeier-Pfistershammer K; Trauner M; Reiberger T; Peck-Radosavljevic M
    Wien Klin Wochenschr; 2016 Jun; 128(11-12):414-20. PubMed ID: 26659706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection.
    Collins LF; Chan A; Zheng J; Chow SC; Wilder JM; Muir AJ; Naggie S
    Open Forum Infect Dis; 2018 Jan; 5(1):ofx264. PubMed ID: 29308413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
    Poizot-Martin I; Bellissant E; Garraffo R; Colson P; Piroth L; Solas C; Renault A; Bourlière M; Halfon P; Ghosn J; Alric L; Naqvi A; Carrieri P; Molina JM;
    HIV Clin Trials; 2016 Mar; 17(2):63-71. PubMed ID: 27077673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
    Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
    Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs.
    Hartman J; Bichoupan K; Patel N; Chekuri S; Harty A; Dieterich D; Perumalswami P; Branch AD
    World J Gastroenterol; 2015 Nov; 21(43):12430-8. PubMed ID: 26604650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
    Dieterich D; Nelson M; Soriano V; Arastéh K; Guardiola JM; Rockstroh JK; Bhagani S; Laguno M; Tural C; Ingiliz P; Jain MK; Stern JO; Manero M; Vinisko R; Kort J;
    AIDS; 2015 Mar; 29(5):571-81. PubMed ID: 25710287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians.
    Ingiliz P; Rockstroh JK
    Liver Int; 2012 Sep; 32(8):1194-9. PubMed ID: 22510096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telaprevir or boceprevir in HIV/HCV-1 co-infected patients in a real-life setting. Interim analysis (24 weeks). COINFECOVA-SEICV study.
    Minguez C; Ortega E; Flores J; Carmena J; Masiá M; Montero M; Reus S; Tornero C; Galindo MJ; Garcia-Deltoro M; Amador C; Cuadrado JM; Usó J; López-Aldeguer J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19634. PubMed ID: 25394138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing HIV/hepatitis C co-infection in the era of direct acting antivirals.
    Rockstroh JK; Bhagani S
    BMC Med; 2013 Nov; 11():234. PubMed ID: 24228933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.